Manufacturing boost for rare disease drugmaker
Horizon Therapeutics to purchase production facility from Irish specialty care company
Horizon Therapeutics plc, which focuses on researching, developing and commercializing medicines for rare, autoimmune and severe inflammatory diseases, has reached an agreement to acquire a drug product manufacturing facility from EirGen Pharma, an OPKO Health company in Waterford, Ireland, that develops and provides high potency specialty care medicines to patients.
The 44,000 square-foot site, which is located in an IDA Ireland business park, includes a filling line and lyophiliser, or freeze dryer, that can be used for both Horizon’s commercial biologics and its development compounds.
Horizon will be working with Ireland’s Health Products Regulatory Agency (HPRA) and the FDA to obtain HPRA and FDA licensure for sterile fill-finish manufacturing. As part of the deal, about 40 EirGen employees will transfer to Horizon after the close of the transaction. This year and next, Horizon also intends to sign on 50 additional staff members for the site.
Touchlight, University of Nottingham Collaborate on Development of Zika Vaccine
August 21st 2024Although it still has to undergo the preclinical and clinical trial process, the DNA vaccine—which could be created in as little as six weeks—does not require the cold chain storage that mRNA jabs often demand.
